News | October 23, 2014

One-year Outcomes Good for Superficial Femoral Artery Stent

October 23, 2014 — The use of stents has improved management and outcomes of coronary artery disease, and clinical trials are attempting to prove the same will be true for superficial femoral artery disease. Randomized trials have shown favorable results for self-expanding nitinol stents compared with balloon angioplasty. A new report seeks to test this treatment in a real-world population of patients enrolled in an observational registry.

The Journal of Endovascular Therapy offers a prospective multicenter observational study of patients with symptomatic superficial femoral artery stenosis. A total of 998 patients suffering from chronic limb ischemia were enrolled at 13 German medical centers. Twelve-month outcomes of the participants were assessed.

The median lesion length was 8 cm, but there was no restriction on the length of lesion to be treated. The authors cite this criterion as supporting the real-world aspect of the study population. Rather than including primarily high-risk patients, a general mix of patients participated in the study. However, a third of the patients had diabetes, and 43 percent were current smokers.

In all, 1,050 lesions were treated. Twelve months after surgery, target lesion revascularization — the primary endpoint of the study — was achieved in 136, or 17 percent, of the patients. Restenosis occurred in 24 percent of the patients and reocclusion in 10 percent. These results indicate that stent use is safe and is delivering favorable outcomes at the one-year mark.

A commentary in the same issue asserts that the “real-world” study group is actually representative of a narrower set of patients, largely because the median lesion length was less than 10 cm—a length that has previously shown good success with intervention. The author notes that, although the study validates that superficial femoral artery stenting is producing satisfactory patency results, patient quality of life and functionality measures might better represent success.

For more information: www.jeytonline.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now